The expenditure includes two deals, including one for $185 million to acquire Incline Therapeutics, a company developing a device to manage post-operative pain.
The other deal is for $105 million for a two-year license to market Bristol-Myers Squibb’s device to control surgical bleeding.
Incline’s patient-controlled analgesia system called IONSYS is for short-term management of acute post-operative pain.
More Articles on Anesthesia:
Anesthesia Machine Sales Expected to Increase by 2014
FDA Does Not Approve Zogenix’s Zohydro Opioid Pain Medication
Dr. Brett Anderson Named Heritage Valley Chair of Anesthesiology
